Rhumbline Advisers Fibrogen Inc Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$0.89 - $2.36 $87,308 - $231,513	-98,099 Reduced 62.39%	59,141 $52,000
Q1 2024 May 09, 2024	BUY	$0.73 - $2.73 $1,954 - $7,308	2,677 Added 1.73%	157,240 $369,000
Q4 2023 Feb 08, 2024	SELL	$0.38 - $0.91 $9 - $21	-24 Reduced 0.02%	154,563 $137,000
Q3 2023 Nov 09, 2023	SELL	$0.79 - $2.83 $6,954 - $24,912	-8,803 Reduced 5.39%	154,587 $132,000
Q2 2023 Aug 08, 2023	BUY	$2.49 - $20.59 $75,656 - $625,606	30,384 Added 22.84%	163,390 $441,000
Q1 2023 May 11, 2023	BUY	$15.95 - $25.18 $82,684 - $130,533	5,184 Added 4.06%	133,006 $2.48 Million
Q4 2022 Feb 14, 2023	BUY	$13.27 - $17.73 $36,532 - $48,810	2,753 Added 2.2%	127,822 $2.05 Million
Q3 2022 Nov 10, 2022	BUY	$11.4 - $14.6 $140,698 - $180,193	12,342 Added 10.95%	125,069 $1.63 Million
Q2 2022 Aug 11, 2022	BUY	$7.94 - $12.96 $103,140 - $168,350	12,990 Added 13.02%	112,727 $1.19 Million
Q1 2022 May 12, 2022	SELL	$12.02 - $16.79 $53,164 - $74,262	-4,423 Reduced 4.25%	99,737 $1.2 Million
Q4 2021 Feb 10, 2022	BUY	$9.93 - $15.39 $4,091 - $6,340	412 Added 0.4%	104,160 $1.47 Million
Q3 2021 Nov 12, 2021	SELL	$10.18 - $26.64 $28,290 - $74,032	-2,779 Reduced 2.61%	103,748 $1.06 Million
Q2 2021 Aug 05, 2021	BUY	$18.57 - $35.68 $99,758 - $191,672	5,372 Added 5.31%	106,527 $2.84 Million
Q1 2021 May 06, 2021	SELL	$31.0 - $55.72 $343,449 - $617,321	-11,079 Reduced 9.87%	101,155 $3.51 Million
Q4 2020 Feb 10, 2021	SELL	$37.09 - $48.97 $101,515 - $134,030	-2,737 Reduced 2.38%	112,234 $4.16 Million
Q3 2020 Nov 12, 2020	SELL	$40.47 - $45.5 $1.17 Million - $1.32 Million	-28,936 Reduced 20.11%	114,971 $4.73 Million
Q2 2020 Aug 13, 2020	BUY	$32.57 - $42.83 $591,438 - $777,749	18,159 Added 14.44%	143,907 $5.83 Million
Q1 2020 May 06, 2020	SELL	$23.3 - $45.96 $12,954 - $25,553	-556 Reduced 0.44%	125,748 $4.37 Million
Q4 2019 Feb 05, 2020	BUY	$34.58 - $48.06 $184,726 - $256,736	5,342 Added 4.42%	126,304 $5.42 Million
Q3 2019 Oct 23, 2019	SELL	$36.98 - $48.45 $84,721 - $110,998	-2,291 Reduced 1.86%	120,962 $4.47 Million
Q2 2019 Aug 14, 2019	BUY	$35.13 - $55.53 $445,799 - $704,675	12,690 Added 11.48%	123,253 $5.57 Million
Q1 2019 May 01, 2019	SELL	$42.83 - $59.91 $48,697 - $68,117	-1,137 Reduced 1.02%	110,563 $6.01 Million
Q4 2018 Jan 31, 2019	BUY	$37.97 - $60.16 $1.51 Million - $2.4 Million	39,812 Added 55.38%	111,700 $5.17 Million
Q3 2018 Nov 07, 2018	SELL	$56.3 - $67.25 $426,359 - $509,284	-7,573 Reduced 9.53%	71,888 $4.37 Million
Q2 2018 Aug 06, 2018	BUY	$44.9 - $64.95 $419,141 - $606,308	9,335 Added 13.31%	79,461 $4.97 Million
Q1 2018 May 02, 2018	SELL	$45.35 - $61.65 $16,416 - $22,317	-362 Reduced 0.51%	70,126 $3.24 Million
Q4 2017 Feb 09, 2018	SELL	$41.95 - $60.1 $462,834 - $663,083	-11,033 Reduced 13.53%	70,488 $3.34 Million
Q3 2017 Nov 06, 2017	BUY	$33.4 - $53.9 $2.72 Million - $4.39 Million	81,521	81,521 $4.39 Million

Others Institutions Holding FGEN

# of Institutions

Shares Held

47.1M

Call Options Held

387K

Put Options Held

672K

Primecap Management CO Pasadena, CA

9.91M
Shares

$3.47 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

6.8M
Shares

$2.38 Million
0.05% of portfolio
Vanguard Group Inc Valley Forge, PA

5.88M
Shares

$2.06 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

3.91M
Shares

$1.37 Million
0.0% of portfolio
Black Rock Inc. New York, NY

2.41M
Shares

$843,377
0.0% of portfolio

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account